Related Experiment Video
Updated: Aug 6, 2026
Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
Published on: April 5, 2024
Ro 08-2750 increases radiation-induced cytotoxicity in DLBCL by dysregulating the DNA damage response
Lasse Reichstein1, Timo Habig1, Kathrin A Gurke Brücksken1
1Department of Radiation Oncology, Münster University Hospital, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Purpose:
Current research aims to increase treatment efficacy in diffuse large B‑cell lymphoma (DLBCL). Recently, Musashi‑2 (MSI-2) was identified as a negative prognostic marker and potential therapeutic target in DLBCL. Here, we evaluated the effect of the MSI‑2 inhibitor Ro 08-2750 in DLBCL cells.
Methods:
First, we established the effects of Ro 08-2750 on DLBCL in cell viability and clonogenicity assays. Changes in cell cycle and apoptosis were analyzed flow cytometrically. We then evaluated modifications in DLBCL treatment response when combining radiation treatment or chemotherapy with Ro 08-2750. Following confirmation of a Ro 08-2750-associated increase in radiation-induced DNA damage via a γH2AX assay, an immunoblot-based assay was used to detect changes in radiation-induced DNA damage repair protein activation. To understand Ro 08-2750-induced modifications in gene expression and protein abundance, we performed RT-qPCR, bulk mRNA-sequencing, western blotting, and quantitative mass spectrometry-based proteomic analyses.
Results:
Ro 08-2750 reduced cell viability and proliferation in DLBCL. Functionally, Ro 08-2750 induced cell cycle arrest in the S phase, where the DNA synthesis rate was attenuated. Additionally, apoptosis was increased. Ro 08-2750 also sensitized DLBCL cell lines to irradiation but not to chemotherapy, and it increased irradiation-induced DNA double-strand breaks. Transcriptome and proteome analyses showed changes in various tumor-associated signaling pathways, primarily associating Ro 08-2750 with compromised DNA repair, cell cycle, and cell division.
Conclusion:
We identified Ro 08-2750 as a radiosensitizer in DLBCL. Our results suggest that the combination of Ro 08-2750 with radiation therapy may enhance treatment efficacy.
Insights
The Musashi-2 inhibitor Ro 08-2750 shows promise for treating diffuse large B-cell lymphoma (DLBCL). This MSI-2 inhibitor enhances radiation therapy efficacy by increasing DNA damage and apoptosis in DLBCL cells.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Diffuse large B-cell lymphoma (DLBCL) remains a significant challenge in hematologic oncology.
- Musashi-2 (MSI-2) is implicated as a negative prognostic marker and potential therapeutic target in DLBCL.
- Developing novel therapeutic strategies to improve DLBCL treatment outcomes is crucial.
Purpose of the Study:
- To evaluate the efficacy of the MSI-2 inhibitor Ro 08-2750 in DLBCL cells.
- To determine the effects of Ro 08-2750 on DLBCL cell viability, proliferation, cell cycle, and apoptosis.
- To assess the potential of Ro 08-2750 in combination with existing therapies like radiation and chemotherapy.
Main Methods:
- Cell viability and clonogenicity assays were performed to assess Ro 08-2750's impact on DLBCL cells.
- Flow cytometry was utilized to analyze cell cycle progression and apoptosis.
- Combination studies with radiation and chemotherapy were conducted, alongside DNA damage assays (γH2AX) and protein analysis.
- RT-qPCR, mRNA sequencing, western blotting, and proteomic analyses were employed to investigate molecular changes.
Main Results:
- Ro 08-2750 significantly reduced DLBCL cell viability and proliferation.
- The inhibitor induced S-phase cell cycle arrest, attenuated DNA synthesis, and increased apoptosis.
- Ro 08-2750 sensitized DLBCL cells to irradiation, enhancing DNA double-strand breaks, but not chemotherapy.
- Molecular analyses revealed that Ro 08-2750 compromises DNA repair, cell cycle, and cell division pathways.
Conclusions:
- Ro 08-2750 acts as a radiosensitizer in DLBCL.
- Combining Ro 08-2750 with radiation therapy holds potential for enhancing DLBCL treatment efficacy.
- Targeting MSI-2 with Ro 08-2750 represents a promising strategy for DLBCL management.
